Brazil institute says CoronaVac efficacy above 50pct, but delays full results



Brazilian researchers said on Wednesday the Covid-19 vaccine developed by China's Sinovac Biotech is more than 50 percent effective based on trial data, but again withheld full results at the company's request, raising questions about transparency.

Brazil is the first country to complete a late-stage trial of the vaccine, called CoronaVac, but a release of the results, first set for early December, has now been delayed three times...

All Access Plan
starting from


per month
Subscribe Now
You can cancel anytime.
Get unlimited access to our articles on web and apps
Add comments to our articles
Bookmark articles to read later
We accept
Student or Senior Citizen? Get a special rateGroup / Institutional / Corporate Plans
Already Subscribed?
Sign In